| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
19,433 |
18,396 |
$472K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
5,103 |
4,911 |
$97K |
| 80373 |
|
9,743 |
9,413 |
$92K |
| 80354 |
|
9,711 |
9,382 |
$89K |
| 80369 |
|
9,742 |
9,412 |
$86K |
| 80365 |
|
9,718 |
9,387 |
$86K |
| 80356 |
|
9,342 |
9,020 |
$85K |
| 80362 |
|
9,451 |
9,133 |
$79K |
| 80348 |
|
9,426 |
9,109 |
$79K |
| 80372 |
|
9,728 |
9,396 |
$76K |
| 80335 |
|
9,446 |
9,125 |
$64K |
| 80355 |
|
9,464 |
9,145 |
$61K |
| 80358 |
|
8,951 |
8,383 |
$60K |
| 80305 |
|
16,729 |
16,085 |
$58K |
| 80350 |
|
8,633 |
8,376 |
$58K |
| 80366 |
|
9,449 |
9,127 |
$54K |
| 80346 |
|
5,941 |
5,813 |
$48K |
| 80367 |
|
9,370 |
9,047 |
$41K |
| 80359 |
|
8,633 |
8,370 |
$41K |
| 80323 |
|
3,315 |
3,156 |
$38K |
| 80357 |
|
8,385 |
8,131 |
$36K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
1,091 |
907 |
$25K |
| 80371 |
|
6,027 |
5,834 |
$24K |
| 80345 |
|
3,047 |
2,901 |
$19K |
| 80338 |
|
3,049 |
2,903 |
$19K |
| 80360 |
|
3,050 |
2,904 |
$15K |
| 96367 |
|
1,085 |
903 |
$12K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
6,732 |
6,205 |
$12K |
| 83992 |
|
2,602 |
2,552 |
$11K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
153 |
153 |
$8K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
9,620 |
9,233 |
$6K |
| 80324 |
|
1,348 |
1,317 |
$2K |
| 80364 |
|
243 |
230 |
$1K |
| 80353 |
|
261 |
248 |
$814.20 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
83 |
82 |
$743.75 |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
426 |
381 |
$600.00 |
| 62369 |
|
28 |
27 |
$497.88 |
| 76942 |
|
26 |
26 |
$455.16 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
228 |
195 |
$243.00 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
30 |
30 |
$185.64 |
| 84311 |
|
186 |
168 |
$27.43 |
| 99443 |
|
126 |
120 |
$20.34 |
| 83986 |
|
186 |
168 |
$15.12 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
1,260 |
1,146 |
$6.87 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
788 |
766 |
$0.00 |
| 3725F |
|
797 |
785 |
$0.00 |
| 1124F |
|
620 |
613 |
$0.00 |
| G8539 |
Functional outcome assessment documented as positive using a standardized tool and a care plan based on identified deficiencies is documented within two days of the functional outcome assessment |
120 |
119 |
$0.00 |
| 1100F |
|
123 |
123 |
$0.00 |
| 90832 |
Psychotherapy, 30 minutes with patient |
78 |
76 |
$0.00 |
| L0651 |
Lumbar-sacral orthosis, sagittal-coronal control, rigid shell(s)/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, anterior extends from symphysis pubis to xyphoid, produces intracavitary pressure to reduce load on the intervertebral discs, overall strength is provided by overlapping rigid material and stabilizing closures, includes straps, closures, may include soft interface, pendulous abdomen design, prefabricated, off-the-shelf |
22 |
13 |
$0.00 |
| 90791 |
Psychiatric diagnostic evaluation |
193 |
187 |
$0.00 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
865 |
849 |
$0.00 |
| G2197 |
Patient screened for unhealthy alcohol use using a systematic screening method and not identified as an unhealthy alcohol user |
736 |
722 |
$0.00 |
| M1207 |
Patient is screened for food insecurity, housing instability, transportation needs, utility difficulties, and interpersonal safety |
811 |
799 |
$0.00 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
322 |
318 |
$0.00 |
| G9902 |
Patient screened for tobacco use and identified as a tobacco user |
264 |
262 |
$0.00 |
| G9906 |
Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) |
263 |
262 |
$0.00 |